ArticleJournal of gastrointestinal oncology2013
Understanding and targeting resistance to anti-angiogenic therapies.
Article in Journal of gastrointestinal oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
50 citing papers in PubMed, 83 citations in OpenAlex.
- Targeting Tumour Heterogeneity through sequential timing of anti-hallmark combination therapies -a hypothesis for implementation.Frontiers in immunology · 2026Review
- Cancer-associated fibroblasts: central players in cancer hallmarks and therapeutic resistance.Cell communication and signaling : CCS · 2025Review
- Review
- Fibroblast growth factor receptor expression in hemangioblastomas: A novel therapeutic target.PloS one · 2025Article
- Pan-Cancer Single-Cell Transcriptomic Analysis Reveals Divergent Expression of Embryonic Proangiogenesis Gene Modules in Tumorigenesis.Cancer medicine · 2024Article
- Review
- Learning Individual Survival Models from PanCancer Whole Transcriptome Data.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023Article
- A Weakly Supervised Deep Learning Method for Guiding Ovarian Cancer Treatment and Identifying an Effective Biomarker.Cancers · 2022Article
- The tumour immune microenvironment in oesophageal cancer.British journal of cancer · 2021Review
- Anti-angiogenesis in cancer therapeutics: the magic bullet.Journal of the Egyptian National Cancer Institute · 2021Review
- Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture.World journal of gastrointestinal oncology · 2021Article
- Nanomaterials for Antiangiogenic Therapies for Cancer: A Promising Tool for Personalized Medicine.International journal of molecular sciences · 2021Review
- From Conventional to Precision Therapy in Canine Mammary Cancer: A Comprehensive Review.Frontiers in veterinary science · 2021Review
- HOX Genes Family and Cancer: A Novel Role for Homeobox B9 in the Resistance to Anti-Angiogenic Therapies.Cancers · 2020Review
- CD105 is a prognostic marker and valid endothelial target for microbubble platforms in cholangiocarcinoma.Cellular oncology (Dordrecht, Netherlands) · 2020Article
- Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancer.Scientific reports · 2020Article
- Resistance Mechanisms to Anti-angiogenic Therapies in Cancer.Frontiers in oncology · 2020Review
- High expression of apoptosis protein (Api-5) in chemoresistant triple-negative breast cancers: an innovative target.Oncotarget · 2019Article
- Article
- SNX9 determines the surface levels of integrin β1 in vascular endothelial cells: Implication in poor prognosis of human colorectal cancers overexpressing SNX9.Journal of cellular physiology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapies targeting tumor angiogenesis are used in a variety of malignancies, however not all patients benefit from treatment and impact on tumor control may be transient and modest. Mechanisms of resistance to anti-angiogenic therapies can be broadly categorized into VEGF-axis dependent alterations, non-VEGF pathways, and stromal cell interactions. Complimentary combinations of agents that inhibit alternative mechanisms of blood vessel formation may optimize inhibition of angiogenesis and improve clinical benefit for patients. The purpose of this review is to detail the preclinical evidence for mechanisms of angiogenic resistance and provide an overview of novel therapeutic approaches exploiting these pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.